Skip to results

Keyword or reference number

Keyword or reference number

Last updated date

Last updated date

Area of interest

Area of interest

Type

Type

Guidance programme (1 selected)

Guidance programme

Showing 751 to 775 of 872

Published guidance, NICE advice and quality standards
TitleReference numberPublishedLast updated
Bevacizumab in combination with gemcitabine and carboplatin for treating the first recurrence of platinum-sensitive advanced ovarian cancerTA285
Loxapine inhalation for treating acute agitation and disturbed behaviours associated with schizophrenia and bipolar disorder (terminated appraisal)TA286
Omalizumab for treating severe persistent allergic asthmaTA278
Percutaneous vertebroplasty and percutaneous balloon kyphoplasty for treating osteoporotic vertebral compression fracturesTA279
Colistimethate sodium and tobramycin dry powders for inhalation for treating pseudomonas lung infection in cystic fibrosisTA276
Methylnaltrexone for treating opioid-induced bowel dysfunction in people with advanced illness receiving palliative care (terminated appraisal)TA277
Vinflunine for the treatment of advanced or metastatic transitional cell carcinoma of the urothelial tractTA272
Tadalafil for the treatment of symptoms associated with benign prostatic hyperplasia (terminated appraisal)TA273
Ipilimumab for previously treated advanced (unresectable or metastatic) melanomaTA268
Decitabine for the treatment of acute myeloid leukaemia (terminated appraisal)TA270
Dronedarone for the treatment of non-permanent atrial fibrillationTA197
Ivabradine for treating chronic heart failureTA267
Mannitol dry powder for inhalation for treating cystic fibrosisTA266
Denosumab for the prevention of skeletal-related events in adults with bone metastases from solid tumoursTA265
Alteplase for treating acute ischaemic strokeTA264
Bevacizumab in combination with capecitabine for the first-line treatment of metastatic breast cancerTA263
Rivaroxaban for the treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolismTA261
Lapatinib or trastuzumab in combination with an aromatase inhibitor for the first-line treatment of metastatic hormone receptor-positive breast cancer that overexpresses HER2TA257
Erlotinib for the first-line treatment of locally advanced or metastatic EGFR-TK mutation-positive non-small-cell lung cancerTA258
Botulinum toxin type A for the prevention of headaches in adults with chronic migraineTA260
Fingolimod for the treatment of highly active relapsing–remitting multiple sclerosisTA254
Tocilizumab for the treatment of rheumatoid arthritisTA247
Cetuximab, bevacizumab and panitumumab for the treatment of metastatic colorectal cancer after first-line chemotherapyTA242
Rituximab for the first-line treatment of stage III-IV follicular lymphomaTA243
Apixaban for preventing venous thromboembolism after hip or knee replacement surgeryTA245

Results per page

  1. 10
  2. 25
  3. 50
  4. All